论文部分内容阅读
AIM:Attaining hepatitis B e antigen(HBeAg)seroconversionduring lamivudine treatment is associated with fewer relapsesin HBeAg-positive patients.In HBeAg-negative patients,predictors for post-treatment relapse remain largely unknown.We therefore studied whether end-of-treatment virologicresponse correlated with relapse after lamivudine treatment.METHODS:We prospectively analyzed 12 HBeAg-negativepatients and 14 HBeAg-positive patients with chronic hepatitisB,who received at least 9 mo of lamivudine treatment andwere followed up for 12 mo post-treatment.Relapse ofhepatitis B activity was defined by an elevation of serumALT level above twice the upper limit of normal as well asreappearance of serum HBV DNA by the branched DNA assayor HBeAg during the follow-up period.The serum viral loadsduring and at the end of treatment were further determinedby a quantitative real-time polymerase chain reaction assay.RESULTS:Relapse occurred in 6(50.0%)HBeAg-negativepatients within 12 mo post-treatment.Two relapsers hadend-of-treatment serum viral load<1 000 copies/mL,theproportion was not significantly different from that in the 6non-relapsers(33.3% vs 16.7%;P=1.00).Hepatitis B virus(HBV)DNA levels did not correlate with post-treatmentrelapse in HBeAg-positive patients either.However,genotypeC patients tended to have a lower relapse rate than genotypeB patients(14.3% vs57.9%,P=0.08).CONCLUSION:Our results suggest that end-of-treatmentvirologic response cannot predict post-treatment relapse inpatients with HBeAg-negative or-positive chronic hepatitisB.The impact of HBV genotype on the response to lamivudinetreatment awaits further studies.
AIM: Attaining hepatitis B e antigen (HBeAg) seroconversionduring lamivudine treatment is associated with fewer relapsesin HBeAg-positive patients. In HBeAg-negative patients, predictors for post-treatment relapsently still unknown. We therefore study whether end-of-treatment virologicresponse correlated with relapse after lamivudine treatment. METHODS: We prospectively analyzed 12 HBeAg-negativepatients and 14 HBeAg-positive patients with chronic hepatitisB, who received at least 9 mo of lamivudine treatment and follow-up for 12 mo post-treatment. Relapse of hepatopathy B activity was defined by an elevation of serumALT level above twice the upper limit of normal as well asreappearance of serum HBV DNA by the branched DNA assayor HBeAg during the follow-up period. The serum viral loads and at the end of treatment were further determined by a quantitative real- time polymerase chain reaction assay .RESULTS: Relapse occurred in 6 (50.0%) HBeAg-negativepatients within 12 months post-treatment .Two relapsers hadend-of-treatment serum viral load <1 000 copies / mL, theproportion was not significantly different from that in 6 in-relapsers (33.3% vs 16.7%; P = 1.00) .Hepatitis B virus did not correlate with post-treatment lapse in HBeAg-positive patients either. Host, genotype C patients tended to have a lower relapse rate than genotype B patients (14.3% vs 57.9%, P = 0.08) .CONCLUSION: Our results suggest that end-of -treatmentvirologic response can not predict post-treatment relapse inpatients with HBeAg-negative or -positive chronic hepatitis B. The impact of HBV genotype on the response to lamivudinetreatment awaits further studies.